4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st

SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

SAN CARLOS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it will host an investor day to provide an overview of its antibody therapeutic pipeline and unique APXiMAB™ platform on Monday, May 16, 2022. The company will discuss lead asset sotigalimab's Phase 2 development program with a focus on melanoma, esophageal/GEJ cancer and sarcoma indications, its positioning in the competitive landscape, key data to date and upcoming milestones. The company will also highlight its promising preclinical program

- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

Brookline Capital Markets is hosting the Brookline Capital Markets Biotech Symposium today at the International Tennis Hall of Fame in Newport, Rhode Island. The theme of the meeting is "Transformative Biotech – Cancer, Rare Diseases, and Viruses." Participants include private and publicly traded biotechnology companies and a group of knowledgeable healthcare investors. The agenda includes company presentations in 1:1 and small group meetings along with relevant topical panels. Presenters include senior executives of leading biotechnology companies and key opinion leaders discussing advances in oncology, rare diseases, and infectious diseases. The Conference reflects Brookline's focus on

SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

SC 13G - Apexigen, Inc. (0001814140) (Subject)

SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)

SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)

SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)